PSYCHIC AND SOMATIC COMPLAINTS IN FEMALES AFTER SURGICALLY INDUCED POSTMENOPAUSE AND THEIR MANAGEMENT

No abstrac

Histological-functional characteristic of vegetative organs of Mentha piperita L. in the conditions of the Zaporozhye region

Робота присвячена гістолого-функціональній характеристиці вегетативних органів Mentha piperita в умовах Запорізької області. Наведено відсоткове співвідношення тканих вегетативних органів (листка, стебла, кореня), визначена екологічна група Mentha piperita в залежності від волог

Досвід вирощування, заготівлі та використання рослинного матеріалу малопоширених сільськогосподарських культур в аранжуванні

The authored works, including dry plant material, are recently becoming increasingly popular. Artistic compositions made of preserved plants do not require special care, and in combination with interesting materials look bright and spectacular and preserve the natural beauty of plants for a long time. Modern preservation technology of the arrangement material allows ensuring its high quality; therefore it is as beautiful and original as live flowers. During the study the authors applied special and general research techniques, laboratory and phytodynamics in particular. We have revealed that that fruits (inflorescences) of rare agricultural crops have high decorative character and can be used as dry (preserved) vegetative material in volumetric and semispecific varieties of compositions as a forming, main and secondary material. These are such plants as ordinary cotton, bamia, kenaf, cannate, safflower dipping and thistle spotted. It is advisable to use a natural way of bulk preservation for them, i.e. drying in the field. In addition, the benefits of this plant material are its originality, accessibility, ease of cultivation and storage duration. It can be used in the learning process to get skills for creating tracks for students. The results of visual perennial observations showed a high drought tolerance of these plants in the conditions of the Agrobiological complex of Bogdan Khmelnitsky Melitopol State Pedagogical University. The investigated plants without noticeable damage can withstand prolonged periods of drought, which are characteristic for the Southern steppe and do not require special conditions of cultivation. Thus, on the basis of the given data, we believe that the study of the decorative qualities of some types of rare crops, the characteristics of cultivation and evaluation of compositional use are the basis for their application in decorative floristics and the expansion of the plant range that can be used to make compositions throughout the year.Встановлено, що малопоширені сільськогосподарські культури можна використовувати як сухий (консервований) рослинний матеріал в об'ємному та напівоб'ємному різновидах композицій. Це такі рослини, як: бавовник звичайний, бамія, кенаф, канатник, сафлор красильний та розторопша плямиста. Результати візуальних багаторічних спостережень показали високу посухостійкість цих рослин в умовах Агробіологічного комплексу МДПУ ім. Б. Хмельницького. Досліджувані рослини без помітних пошкоджень витримують затяжні періоди посухи, які характерні для Південного Степу та не потребують особливих умов вирощування. Окремо для кожної культури визначено особливості заготівлі аранжувального матеріалу – термін збирання, консервування та умови зберігання. З'ясовано, що плоди або суцвіття цих рослин мають декоративні властивості, їх можна використовувати в композиціях як формоутворювальний основний рослинний матеріал та як матеріал-наповнювач. Для них доцільно використовувати природний спосіб об'ємного консервування – сушіння в польових умовах на колекційній ділянці. Окрім цього, перевагами цього рослинного матеріалу є його оригінальність, доступність, простота вирощування та тривалість зберігання. Оскільки ці рослини можна вважати перспективними для декоративної флористики, їх доцільно не тільки впроваджувати в навчальний процес під час вивчення дисциплін "Основи аранжування" та "Фітодизайн", але й включати в перелік рекомендованих рослин для аранжування у професійній літературі

Applying plant disturbance indicators to reveal the hemeroby of soil macrofauna species

Hemeroby is an integrated indicator for measuring human impacts on environmental systems. Hemeroby has a complex nature and a variety of mechanisms to affect ecosystems. Hemeroby is often used to assess disturbances in different vegetation types but this con-cept has seldom been evaluated for animals. The role of the hemeroby gradient in structuring the soil macrofauna community was inves-tigated. The experimental polygon was located in Botanical Garden of the Oles Honchar Dnipro National University (Dnipro City, Ukraine). There were 20 sites within the polygon. On each of them at 105 points samples of soil macrofauna were taken, soil penetration resistance, electrical conductivity of soil, depth of litter, height of grasses were measured. Within each site, a description of the vegetation cover was made. Based on the description of the vegetation, an indication of the level of ecosystem hemeroby within the polygons was conducted. In total, 48,457 invertebrate (Annelida, Arthropoda, and Mollusca) individuals of 6 classes, 13 orders, 50 families and 83 species or parataxonomic units were recorded. Phytoindication reveals that the level of hemeroby within the studied polygons varies from 34.9 to 67.2. The model V and VI from the HOFJO-list were the most optimal model of the species response to hemeroby gra-dient. The weighted average factor value was used to assess the optimal factor level for the species in a symmetrical bell-shaped re-sponse model. The optimal factor level of the hemeroby for the soil macrofauna species ranges from 34.9 to 66.0. Species also differ in degree of specialization to the factor of hemeroby. There was a regular change in the soil macrofauna community size and diversity in the hemeroby gradient. The limiting influence of anthropogenic transformation of the environment on the abundance of soil macrofauna community is clearly marked at the level of hemeroby above average. Species diversity of the community is greatest at moderate heme-roby level. Both relatively little transformed habitats and strongly transformed ones are characterized by lower species richness of the soil macrofauna community. The Shannon index shows a clear upward trend with increasing hemeroby. The Pielou index indicates that the main reason for this trend is an increase in community evenness with increasing hemeroby. The intermediate disturbance hypothesis was fully supported with respect to species richness. For the number of species, there is indeed a certain level of heterogeneity at which the number of species is highest. For another aspect of diversity, evenness, this pattern is not true. The evenness increases with increas-ing habitat disturbance. This result is due to a decrease in the abundance of dominant species. Keywords: diversity; urbanization; bioindication; canonical correspondance analysis; variation fractioning

European Society for Immunodeficiencies guidelines for the management of patients with congenital athymia

\ua9 2024 The AuthorsCongenital athymia is a life-limiting disorder due to rare inborn errors of immunity causing impaired thymus organogenesis or abnormal thymic stromal cell development and function. Athymic infants have a T-lymphocyte–negative, B-lymphocyte–positive, natural killer cell–positive immunophenotype with profound T-lymphocyte deficiency and are susceptible to severe infections and autoimmunity. Patients variably display syndromic features. Expanding access to newborn screening for severe combined immunodeficiency and T lymphocytopenia and broad genetic testing, including next-generation sequencing technologies, increasingly facilitate their timely identification. The recommended first-line treatment is allogeneic thymus transplantation, which is a specialized procedure available in Europe and the United States. Outcomes for athymic patients are best with early diagnosis and thymus transplantation before the development of infectious and inflammatory complications. These guidelines on behalf of the European Society for Immunodeficiencies provide a comprehensive review for clinicians who manage patients with inborn thymic stromal cell defects; they offer clinical practice recommendations focused on the diagnosis, investigation, risk stratification, and management of congenital athymia with the aim of improving patient outcomes

Recommendations for Transitioning Young People with Primary Immunodeficiency Disorders and Autoinflammatory Diseases to Adult Care

\ua9 The Author(s) 2024.Purpose: Significant improvements in the prognosis for young patients with Primary Immunodeficiency Diseases (PID) and Autoinflammatory Disorders (AID), which together make up the majority of Inborn Errors of Immunity (IEI), have resulted in the need for optimisation of transition and transfer of care to adult services. Effective transition is crucial to improve health outcomes and treatment compliance among patients. Evaluations of existing transition programmes in European health centres identified the absence of disease-specific transition guidelines for PID and AID, as a challenge to the transition process. This research aimed to establish expert consensus statements for the transition of young patients with PID and AID to adult services. Methods: This project used the Delphi method to establish mutual agreement for the proposed recommendations. A draft set of statements was developed following a literature review of existing transition programmes. Then the ERN RITA Transition Working Group convened to review the drafted recommendations and develop them into a survey. This survey was circulated among healthcare professionals to determine consensus using a five-point Likert scale, with the level of agreement set to 80% or greater. Statements that did not reach consensus were revised by the Working Group and recirculated among respondents. Results: The initial survey received 93 responses from 68 centres across 23 countries, while the following survey outlining revised recommendations received 66 responses. The respondents agreed upon recommendations detailing the structure and administration of transition programmes, collaborative working with social systems, and contraindications to transfer of care. Conclusion: This paper sets out a comprehensive set of recommendations to optimise transitional care for PID and AID

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402